524 related articles for article (PubMed ID: 23743858)
1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
2. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
3. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
[TBL] [Abstract][Full Text] [Related]
4. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance.
Carulli G; Ottaviano V; Cannizzo E; Giuntini S; Manetti C; Ciancia EM; Azzarà A
Clin Ter; 2012; 163(5):387-92. PubMed ID: 23099966
[TBL] [Abstract][Full Text] [Related]
5. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
[TBL] [Abstract][Full Text] [Related]
6. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
Sezer O; Heider U; Zavrski I; Possinger K
Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
9. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
[TBL] [Abstract][Full Text] [Related]
10. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos L; Tamariz-Amador LE; Puig N; Cedena MT; Guerrero C; Jelínek T; Johnson S; Milani P; Cordon L; Perez JJ; Lasa M; Termini R; Oriol A; Hernandez MT; Palomera L; Martinez-Martinez R; de la Rubia J; de Arriba F; Rios R; Gonzalez ME; Gironella M; Cabañas V; Casanova M; Krsnik I; Perez-Montaña A; González-Calle V; Rodriguez-Otero P; Maisnar V; Hajek R; Van Rhee F; Jimenez-Zepeda V; Palladini G; Merlini G; Orfao A; de la Cruz J; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B;
J Clin Oncol; 2023 Jun; 41(16):3019-3031. PubMed ID: 36930848
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma].
Schleiffenbaum BE
Praxis (Bern 1994); 2012 Nov; 101(24):1521-9; quiz 1530-1. PubMed ID: 23184544
[No Abstract] [Full Text] [Related]
15. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
[TBL] [Abstract][Full Text] [Related]
16. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
17. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.
Raja KR; Kovarova L; Hajek R
Br J Haematol; 2010 May; 149(3):334-51. PubMed ID: 20201947
[TBL] [Abstract][Full Text] [Related]
18. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Br J Haematol; 2008 Apr; 141(2):205-11. PubMed ID: 18318761
[TBL] [Abstract][Full Text] [Related]
19. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]